This study investigates KRAS-mutated solid tumors. It evaluates the effects of an investigational mRNA vaccine.
The study focuses on assessing safety and how well the body responds to the vaccine. It also looks at how the vaccine works when used alone or with another treatment.
- Who can participate: Adults 18 years and older with advanced solid tumors and a specific KRAS mutation may participate. Participants must have experienced disease progression or intolerance to previous treatments and have a life expectancy of at least 12 weeks.
- Study details: Participants will receive an investigational mRNA vaccine. Some may also receive an inactive substance called a placebo, which looks like the investigational vaccine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand